Vladimir A. Pavlyukovets
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vladimir A. Pavlyukovets.
Journal of Computer-aided Molecular Design | 2011
Jin Hee Lee; Yoonji Lee; HyungChul Ryu; Dong Wook Kang; Jeewoo Lee; József Lázár; Larry V. Pearce; Vladimir A. Pavlyukovets; Peter M. Blumberg; Sun Choi
The transient receptor potential vanilloid subtype 1 (TRPV1) is a non-selective cation channel composed of four monomers with six transmembrane helices (TM1–TM6). TRPV1 is found in the central and peripheral nervous system, and it is an important therapeutic target for pain relief. We describe here the construction of a tetrameric homology model of rat TRPV1 (rTRPV1). We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX). We then performed docking analysis using our homology model. The docking results with capsaicin and RTX showed that our homology model was reliable, affording good agreement with our mutation data. Additionally, the binding mode of a simplified RTX (sRTX) ligand as predicted by the modeling agreed well with those of capsaicin and RTX, accounting for the high binding affinity of the sRTX ligand for TRPV1. Through the homology modeling, docking and mutational studies, we obtained important insights into the ligand-receptor interactions at the molecular level which should prove of value in the design of novel TRPV1 ligands.
Bioorganic & Medicinal Chemistry | 2012
Yong-Soo Kim; Min-Jung Kil; Sang-Uk Kang; HyungChul Ryu; Myeong Seop Kim; Yongsung Cho; Rahul S. Bhondwe; Shivaji A. Thorat; Wei Sun; Keliang Liu; Jin Hee Lee; Sun Choi; Larry V. Pearce; Vladimir A. Pavlyukovets; Matthew A. Morgan; József Lázár; Peter M. Blumberg; Jeewoo Lee
Structure-activity relationships for the A-region in a series of N-4-t-butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamides as TRPV1 antagonists have been investigated. Among them, the 3-fluoro analogue 54 showed high binding affinity and potent antagonism for both rTRPV1 and hTRPV1 in CHO cells. Its stereospecific activity was demonstrated with marked selectivity for the (S)-configuration (54S versus 54R). A docking study of 54S with our hTRPV1 homology model highlighted crucial hydrogen bonds between the ligand and the receptor contributing to its potency.
Bioorganic & Medicinal Chemistry | 2009
Hyun-Kyung Choi; Sun Choi; Yoonji Lee; Dong Wook Kang; HyungChul Ryu; Han-Joo Maeng; Suk-Jae Chung; Vladimir A. Pavlyukovets; Larry V. Pearce; Attila Tóth; Yun Wang; Matthew A. Morgan; Peter M. Blumberg; Jeewoo Lee
A series of non-vanillyl resiniferatoxin analogues, having 4-methylsulfonylaminophenyl and fluorophenyl moieties as vanillyl surrogates, have been investigated as ligands for rat TRPV1 heterologously expressed in Chinese hamster ovary cells. Although lacking the metabolically problematic 4-hydroxy substituent on the A-region phenyl ring, the compounds retained substantial agonist potency. Indeed, the 3-methoxy-4-methylsulfonylaminophenyl analog (1) was modestly (2.5-fold) more potent than RTX, with an EC(50)=0.106 nM. Further, it resembled RTX in its kinetics and pattern of stimulation of the levels of intracellular calcium in individual cells, as revealed by imaging. Compound 1 displayed modestly enhanced in vitro stability in rat liver microsomes and in plasma, suggesting that it might be a pharmacokinetically more favorable surrogate of resiniferatoxin. Molecular modeling analyses with selected analogues provide evidence that the conformational differences could affect their binding affinities, especially for the ester versus amide at the B-region.
Bioorganic & Medicinal Chemistry | 2010
Dong Wook Kang; Yong-Soo Kim; Kwang Su Lim; Myeong Seop Kim; Larry V. Pearce; Vladimir A. Pavlyukovets; Andy K. Tao; Krystle A. Lang-Kuhs; Peter M. Blumberg; Jeewoo Lee
As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3-methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I>Br>Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with K(i) (ant)=2.77 and 2.19nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6-iodononivamide.
Bioorganic & Medicinal Chemistry Letters | 2012
Rahul S. Bhondwe; Dong Wook Kang; Myeong Seop Kim; Ho Shin Kim; Seul-gi Park; Karam Son; Sun Choi; Krystle A. Lang Kuhs; Vladimir A. Pavlyukovets; Larry V. Pearce; Peter M. Blumberg; Jeewoo Lee
The structure-activity relationships of N-(3-acyloxy-2-benzylpropyl)-N-4-[(methylsulfonylamino)benzyl] thioureas, which represent simplified RTX-based vanilloids, were investigated by varying the distances between the four principal pharmacophores and assessing binding and antagonistic activity on rTRPV1. The analysis indicated that a 3-pivaloyloxy-2-benzylpropyl C-region conferred the best potency in binding affinity and antagonism. The molecular modeling of this best template with the tetrameric homology model of rTRPV1 was performed to identify its binding interactions with the receptor.
Bioorganic & Medicinal Chemistry Letters | 2014
Ho Shin Kim; Mi-Kyoung Jin; Sang-Uk Kang; Ju-Ok Lim; Phuong-Thao Tran; Van-Hai Hoang; Jihyae Ann; Tae-Hwan Ha; Larry V. Pearce; Vladimir A. Pavlyukovets; Peter M. Blumberg; Jeewoo Lee
A series of α-methylated analogues of the potent sRTX thiourea antagonists were investigated as rTRPV1 ligands in order to examine the effect of α-methylation on receptor activity. The SAR analysis indicated that activity was stereospecific with the (R)-configuration of the newly formed chiral center providing high binding affinity and potent antagonism while the configuration of the C-region was not significant.
Bioorganic & Medicinal Chemistry | 2012
Wei Sun; Keliang Liu; HyungChul Ryu; Dong Wook Kang; Yong-Soo Kim; Myeong Seop Kim; Yongsung Cho; Rahul S. Bhondwe; Shivaji A. Thorat; Ho Shin Kim; Larry V. Pearce; Vladimir A. Pavlyukovets; Matthew A. Morgan; József Lázár; Christopher B. Ryder; Attila Tóth; Peter M. Blumberg; Jeewoo Lee
On the basis of the previous lead N-4-t-butylbenzyl 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamide (3) as a potent TRPV1 antagonist, structure-activity relationships for the B (propanamide part) and C-region (4-t-butylbenzyl part) have been investigated for rTRPV1 in CHO cells. The B-region was modified with dimethyl, cyclopropyl and reverse amides and then the C-region was replaced with 4-substituted phenyl, aryl alkyl and diaryl alkyl derivatives. Among them, compound 50 showed high binding affinity with K(i)=21.5nM, which was twofold more potent than 3 and compound 54 exhibited potent antagonism with K(i(ant))=8.0nM comparable to 3.
Bioorganic & Medicinal Chemistry Letters | 2012
Yongsung Cho; Myeong Seop Kim; Ho Shin Kim; Ji Hyae Ann; Jiyoun Lee; Larry V. Pearce; Vladimir A. Pavlyukovets; Matthew A. Morgan; Peter M. Blumberg; Jeewoo Lee
A series of TRPV1 agonists with amide, reverse amide, and thiourea groups in the B-region and their corresponding α-methylated analogues were investigated. Whereas the α-methylation of the amide B-region enhanced the binding affinities and potencies as agonists, that of the reverse amide and thiourea led to a reduction in receptor affinity. The analysis indicated that proper hydrogen bonding as well as steric effects in the B-region are critical for receptor binding.
Bioorganic & Medicinal Chemistry Letters | 2005
Jeewoo Lee; Sang-Uk Kang; Min-Jung Kil; Myoungyoup Shin; Ju-Ok Lim; Hyun-Kyung Choi; Mi-Kyoung Jin; Su Yeon Kim; Sung-Eun Kim; Yong-Sil Lee; Kyung-Hoon Min; Young Ho Kim; Hee-Jin Ha; Jacqueline D. Welter; Yun Wang; Tamas Szabo; Larry V. Pearce; Daniel J. Lundberg; Attila Tóth; Vladimir A. Pavlyukovets; Matthew A. Morgan; Peter M. Blumberg
Molecular Pharmacology | 2006
József Lázár; Derek C. Braun; Attila Tóth; Yun Wang; Larry V. Pearce; Vladimir A. Pavlyukovets; Peter M. Blumberg; Susan Garfield; Stephen Wincovitch; Hyun-Kyung Choi; Jeewoo Lee